Is NCT07236190 recruiting in Boston, MA?

Yes, NCT07236190 is currently recruiting participants at its Boston, MA location. This alzheimer disease clinical trial is actively enrolling qualified participants.

How do I join the alzheimer disease clinical trial in Boston?

To join this clinical trial in Boston, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Boston clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Alzheimer Disease Clinical Trial in Boston, MA

About This Alzheimer Disease Study in Boston

This early phase, open label, single arm clinical trial will determine the intraindividual safety, tolerability and effects of NPC1 (parthenolide and ipriflavone) on blood-based biomarkers of Alzheimer's disease (AD) pathology among adults with subjective cognitive decline, mild cognitive impairment, or Alzheimer's disease and objective indicators of seeding AD pathology

Sponsor: Massachusetts General Hospital

Who Can Participate

Inclusion Criteria

Age 55 and older, male and female;

Subjective Cognitive Impairment or MCI or AD dementia per NIA-AA 2011 criteria;

Clinical Dementia Rating \< or = to 2 and Mini Mental Status Exam \> or = to 16;

Modified Hachinski Ischemic Score \< or = to 4

Geriatric Depression Scale - 15 \< 6 documenting absence from significant depressive syndromes

Other medications including non-disease modifying for MCI and AD (e.g., acetylcholine esterase inhibitor, N-methyl D-aspartate receptor antagonist) stable \> or = to 3-months ;

Biomarker evidence of AD pathology: Plasma abeta42/40 ratio \< or = to 0.12 AND Plasma p-tau217 \> or = to 0.25 OR Amyloid PET positive (centiloid \> or = to 20) as part of routine clinical care.

Sufficient vision and hearing to complete all tests

Study partner available with frequent (at least 1 hour/day or 1 day/week) contact with participant to provide collateral information about cognition, daily functioning, adverse events reporting, and support for study drug intake

General health status that will not interfere with the ability to complete the prospective study (these conditions are listed below in the study

Exclusion Criteria

list) Exclusion Criteria:

CDR \> 2 MMSE \< 16;

Significant CNS disease within the last 2 years (i.e., brain tumor, seizure disorder, subdural hematoma, cranial arteritis, cortical stroke);

Alcohol or substance abuse according to DSM-IV criteria within the last 2 years

Major depressive disorder or anxiety within the last year; Schizophrenia, bipolar disorder or other major psychiatric disorder defined by DSM-IV criteria

Abnormal labs indicating potential reversible causes of dementing illness such as vitamin B12 deficiency, thyroid disease, or UTI (documented bacterial colonization is acceptable)

Unstable or significantly symptomatic CVD (e.g. CAD with frequent angina, CHF with dyspnea at rest)

Hypertension: defined as uncontrolled BP \> 160/100

Clinical symptomatic orthostatic hypotension

Diabetes mellitus that requires insulin injections

Hachinski ischemic score \> or = to 4

Cancer within the last 5 years, apart from localized prostate cancer (Gleason Grade \< 3) and non-metastatic skin cancers (melanoma).

Illness that requires \>1 visit /month to a clinician

Medications and dietary supplements:

a. AD disease modifying monoclonal antibody treatment e.g., aducanumab or lecanemab

b. Dietary supplements containing parthenolide or ipriflavone (1-month wash out period prior to enrollment is permitted)

c. CNS active meds that have not been on stable doses for at least 2 months e.g., cimetidine, beta-blockers, and SSRIs

d. Neuroleptics, antiparkinsonian agents, systemic corticosteroids, and narcotic analgesics; in the case where these were used for a self-limited time they must have been discounted for a period of five half-lives prior to baseline visit

e. Over the counter supplements are not by themselves exclusionary, however, participants are asked not to change the dosing regimen over the course of the trial unless medically indicated; the presence and dose of these product are recorded

Participation in any Alzheimer's Disease interventional trial. Participation in other non-AD related trials will be evaluated at the discretion of the investigator

Currently pregnant. Positive pregnancy tests during the course of the trial will be evaluated at the discretion of the investigator. Women of Child Bearing Potential (WOCBP) For the purposes of this study, women of childbearing potential are defined as all women who are capable of becoming pregnant, unless they meet one of the following criteria:

12-months post-menopausal

Post-hysterectomy/surgically sterile If a female Participant does not meet either of these criteria they will be considered of childbearing potential and will have a serum pregnancy test performed at Screening, Visit 3 (2 months), Visit 6 (5 months), and Visit 10 (8 months).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT07236190) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Alzheimer Disease Treatment Options in Boston, MA

If you're searching for alzheimer disease treatment options in Boston, MA, this clinical trial (NCT07236190) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced alzheimer disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all alzheimer disease clinical trials near you to find additional studies recruiting in your area.

Alzheimer Disease Clinical Trial in Boston, MA

Expert Care in Boston

IRB Approved

No-Cost Care

Apply for This Boston Location

Why Participate?

Simple Process